Newsroom

[SFGate] Costly hepatitis C drugs could add $300 to every American’s yearly premium, CVS says

Gilead Sciences’ new hepatitis C drug receives as much praise for its healing powers as it receives criticism of its price, $84,000 for 12 weeks. Those […]

Read more

[Market Watch] CVS officials say Sovaldi pricing in line with history, but unsustainable

Gilead Sciences’ controversial $1,000-a-day Sovaldi pill is priced in line with previous treatments for Hepatitis C, but the nation’s health-care system likely won’t be able to […]

Read more

[SF Business Times ] Three takeaways from Gilead’s Hepatitis C challenge

1. It’s all about price — even when it’s not: Even before Foster City-based Gilead Sciences Inc., led by CEO John Martin, launched its hepatitis C […]

Read more

[The New York Times] $300,000 Drug

There is one other way that Kalydeco is an excellent example of personalized medicine: its cost. It’s more than $300,000 a year. Because patients will likely […]

Read more